IKT – 30-Min Long Trade Setup!📌
🔹 Asset: Inhibikase Therapeutics, Inc. (IKT)
🔹 Timeframe: 30-Min Chart
🔹 Setup Type: Trendline & Triangle Breakout Long Trade
📌 Trade Plan (Long Position)
✅ Entry Zone: Above $3.26 (Breakout Confirmation)
✅ Stop-Loss (SL): Below $3.07 (Break of Support & Trendline)
🎯 Take Profit Targets
📌 TP1: $3.44 (First Resistance Level)
📌 TP2: $3.69 (Final Target – Extended Bullish Move)
📊 Risk-Reward Ratio Calculation
📈 Risk (SL Distance): $3.26 - $3.07 = $0.19 risk per share
📈 Reward to TP1: $3.44 - $3.26 = $0.18 (0.95 R/R)
📈 Reward to TP2: $3.69 - $3.26 = $0.43 (2.26 R/R)
🔍 Technical Analysis & Strategy
📌 Triangle Breakout Setup: The price is breaking out from a symmetrical triangle, signaling potential upside momentum.
📌 Trendline & Support Bounce: Price is holding above the ascending trendline, confirming a bullish structure.
📌 Breakout Confirmation: A strong bullish candle above $3.26 with volume would validate the breakout.
📌 Momentum Shift Expected: A push above $3.26 could lead to a breakout rally toward $3.44 (TP1) and $3.69 (TP2).
📊 Key Support & Resistance Levels
🟢 $3.07 – Strong Support / Stop-Loss Level
🟡 $3.26 – Entry / Breakout Level
🔴 $3.44 – First Resistance / TP1
🟢 $3.69 – Final Target / TP2
🚀 Trade Execution & Risk Management
📊 Volume Confirmation: Ensure strong buying volume above $3.26 before entering.
📈 Trailing Stop Strategy: Move SL to entry ($3.26) after TP1 ($3.44) is hit.
💰 Partial Profit Booking Strategy:
✔ Take 50% profits at $3.44, let the rest run to $3.69.
✔ Adjust Stop-Loss to Break-even ($3.26) after TP1 is reached.
⚠️ Fake Breakout Risk
❌ If price breaks below $3.07, it could indicate a bearish continuation—exit early.
❌ Wait for a strong candle close above $3.26 for confirmation before entering aggressively.
🚀 Final Thoughts
✔ Bullish Setup – Holding above $3.26 could lead to higher targets.
✔ Momentum Shift Possible – Watch for volume confirmation.
✔ Favorable Risk-Reward Ratio – 1:0.95 to TP1, 1:2.26 to TP2.
💡 Stick to the plan, manage risk, and trade smart! 🚀🏆
🔗 #StockTrading #IKT #BreakoutTrade #TechnicalAnalysis #MarketTrends #ProfittoPath #DayTrading #MomentumStocks #SwingTrading #TradingView #LongTrade #TradeSmart #RiskManagement #StockBreakout #Investing #StockAlerts #ChartAnalysis 🚀📈
IKT trade ideas
Inhibikase Therapeutics, Inc. (IKT): Showing Strong MomentumInhibikase Therapeutics, Inc. (IKT) is a biotechnology company focused on developing treatments for neurodegenerative diseases, particularly Parkinson's disease and other related disorders.
The chart pattern shows a confirmation buy bar on increased volume, suggesting that there is strong market interest in Inhibikase's stock. The stock is trading above the Fibonacci .236 support zone, which is a positive sign for potential upward movement. This area, known as the momentum zone, often acts as a launching pad for stocks that maintain their position above it.
The company’s main products are drug candidates that aim to address the underlying causes of these diseases by targeting specific cellular mechanisms. Inhibikase is developing therapies designed to slow or halt the progression of Parkinson’s disease, a condition that currently has no cure.
The company’s most advanced drug candidates include IkT-148009, which is being tested in clinical trials for its potential to treat Parkinson's and other diseases linked to alpha-synuclein protein buildup in the brain.
The main drivers of growth for Inhibikase Therapeutics include advancements in the field of neuroscience, the growing demand for effective treatments for Parkinson's disease, and the company’s ability to progress its drug candidates through clinical trials. As the demand for innovative treatments in the neurology space increases, Inhibikase is positioned to be a key player in providing solutions for patients suffering from debilitating conditions.
The Fibonacci Snap Tool and the Momentum Zones, both available on TradersPro, are the indicators used to analyze the chart. These tools are helpful in identifying key levels of support and resistance and tracking momentum shifts.
IKT Technical Analysis 🧙Inhibikase Therapeutics Inc is a clinical stage pharmaceutical company developing therapeutics for Parkinson's Diseases and related disorders inside and outside the brain. Its pipeline product, IkT-148009, targets underlying disease mechanisms to reverse the course of Parkinson's disease and the GI complications of Parkinson's disease.
If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!